Fulltext

A CRITICAL REVIEW OF PHARMACOECONOMIC STUDIES OF ACAMPROSATE

POLDRUGO, FLAVIO ; HAEGER, DORIS-ANITA ; COMTE, SYLVIE ; WALBURG, JAN ; PALMER, ANDREW J.

In: Alcohol and Alcoholism, 2005, vol. 40, no. 5, p. 422-430

Ajouter à la liste personnelle
    Titre
    • A CRITICAL REVIEW OF PHARMACOECONOMIC STUDIES OF ACAMPROSATE
    Auteur
    • POLDRUGO, FLAVIO. Office for Research and Innovative Projects on Alcohol, Other Addictions and Mental Health, Departments of Psychiatry and Addiction, University of Trieste, Trieste, Italy
    • HAEGER, DORIS-ANITA. Merck Santé, Lyon, France
    • COMTE, SYLVIE. Merck Santé, Lyon, France
    • WALBURG, JAN. Jellinek Klinikum, 1001 AS Amsterdam, Netherlands
    • PALMER, ANDREW J.. CORE Center for Outcomes Research, BASEL, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Alcohol and Alcoholism, 2005, vol. 40, no. 5, p. 422-430. Oxford University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303902
    Summary
    Aims: This review assessed the published data on the cost-effectiveness of acamprosate for the treatment of alcohol dependence. Methods: Four Markov modelling studies have assessed the therapeutic benefit and economic impact of acamprosate on the treatment of alcohol dependence. These have evaluated both short-term and long-term outcomes and have used German, Belgian, and Spanish costings. A fifth prospective cohort study collected real outcomes and data on expenditure during a 1 year study follow-up period. Results: All five studies have produced consistent results, showing the use of acamprosate, which enhances abstinence rates, to reduce the total costs of treatment and thus be dominant over other rehabilitation strategies not involving pharmacotherapy. In all of the studies, the principal cost-driver is hospitalization. Although there is a short-term increase in treatment costs associated with drug acquisition, these are recovered from long-term savings attributable to reduced hospitalization and rehabilitation costs